Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.
about
Human Vascular Microphysiological System for in vitro Drug Screening.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.The Far Side of Vascular Injury: Nonconventional Vasoconstrictors, DNA-targeting Agents, and Agents Toxic to Vascular Smooth Muscle.Regulatory Forum Opinion Piece*: Dispelling Confusing Pathology Terminology: Recognition and Interpretation of Selected Rodent Renal Tubule Lesions.Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development.A bilayer small diameter in vitro vascular model for evaluation of drug induced vascular injuryTechnological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance.Naphthoquine-induced Central Nervous System and Hepatic Vasculocentric Toxicity in the Beagle Dog.Temporal Patterns of Novel Circulating Biomarkers in IL-2-mediated Vascular Injury in the Rat.Use of Rat Primary Mesenteric Cells for the Prediction of PDE4 Inhibitor Drug-Induced Vascular Injury.Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science.
P2860
Q27346581-62FDD64B-E982-497D-A696-C9834BF4E877Q38365365-6B480A75-7DDA-4269-9F6D-575E887021ACQ38365744-3C7003C6-A6D2-47EA-95C3-038E516F0ED9Q38583684-96429BD0-2C8C-401A-9445-7AFFFBA31052Q41079009-65FCF224-3514-4F1C-988F-B16A75380C67Q41584061-1288705E-045C-454C-9DDE-DB1D718DE0E8Q42178673-D7835B38-284D-4CB0-8727-94540163F29AQ45967235-F691C7D4-0DA2-4091-B0B9-D6CAF32201ACQ47949963-757ADEC2-3CF8-4759-8A75-2B29CB2357F4Q48011311-F2B9F943-C516-441C-82D9-5795C4F16197Q50115989-4C51440F-CE88-476A-88F9-200170592393Q52641412-F695B649-2D22-4B28-AC38-0B84651CAF2A
P2860
Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Nonclinical safety biomarkers ...... and blueprint for the future.
@en
Nonclinical safety biomarkers ...... and blueprint for the future.
@nl
type
label
Nonclinical safety biomarkers ...... and blueprint for the future.
@en
Nonclinical safety biomarkers ...... and blueprint for the future.
@nl
prefLabel
Nonclinical safety biomarkers ...... and blueprint for the future.
@en
Nonclinical safety biomarkers ...... and blueprint for the future.
@nl
P2093
P2860
P356
P1476
Nonclinical safety biomarkers ...... and blueprint for the future.
@en
P2093
Bradley E Enerson
Deidre A Dalmas
Holly W Smith
Igor Mikaelian
James L Weaver
Mark Cameron
Marshall S Scicchitano
Michael P Lawton
Nicholas M P King
Peter K Hoffmann
P2860
P304
P356
10.1177/0192623314525686
P407
P577
2014-04-28T00:00:00Z